<DOC>
	<DOC>NCT00077974</DOC>
	<brief_summary>To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma</brief_summary>
	<brief_title>A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Cytokine refractory metastatic renal cell carcinoma with clear cell component Radiographic evidence of disease progression during or within 9 months of completion of 1 cytokine therapy Prior nephrectomy Prior treatment with any systemic therapy other than 1 cytokine therapy History of or known brain metastases Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>